<DOC>
	<DOC>NCT02412644</DOC>
	<brief_summary>12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy</brief_summary>
	<brief_title>Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis</brief_title>
	<detailed_description>Primary Objective: To evaluate the effectiveness of Otezla (apremilast®) in promoting maintenance of response in those subjects who obtained PASI-75 at week 12 of phototherapy.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Subjects must meet the following criteria to be enrolled in this study: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaquetype 3. Moderate to severe plaque type psoriasis as defined at baseline by: PASI score of 12 or greater, PGA score of 3 or greater BSA affected by plaquetype psoriasis of 10% or greater, 4. Able and willing to give written informed consent prior to performance of any studyrelated procedures Subjects who meet any of the following criteria will be excluded from participation in this study: 1. Forms of psoriasis other than chronic plaquetype (e.g., pustular, erythrodermic, and/or guttate psoriasis) or drug induced psoriasis 2. Subjects with previous exposure to apremilast 3. Malignancy or history of malignancy, except for: treated [ie, cured] basal cell or squamous cell in situ skin carcinomas; treated [ie, cured] malignancy with no evidence of recurrence within the previous 5 years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>